Home › Research › Tau biomarkers
Lower CSF Amyloid-Beta1-42 Predicts a Higher Mortality Rate in Frontotemporal Dementia
Daniela Vieira, João Durães, Inês Baldeiras, Beatriz Santiago, Diana Duro, Marisa Lima, Maria João Leitão, Miguel Tábuas-Pereira et al.. Diagnostics (Basel, Switzerland), 2019-10-25
Topic: Plasma and spinal-fluid biomarkers
Frontotemporal lobar degeneration, the neuropathological substrate of frontotemporal dementia (FTD), is characterized by the deposition of protein aggregates, including tau. Evidence has shown concomitant amyloid pathology in some of these patients, which seems to contribute to a more aggressive disease. Our aim was to evaluate cerebrospinal fluid (CSF) amyloid-beta as a predictor of the mortality of FTD patients. We included 99 patients diagnosed with FTD-both behavioral and language variants-with no associated motor neuron disease, from whom a CSF sample was collected. These patients were followed prospectively in our center, and demographic and clinical data were obtained. The survival analysis was carried through a Cox regression model. Patients who died during follow up had a significantly lower CSF amyloid-beta1-42 than those who did not. The survival analysis demonstrated that an increased death rate was associated with a lower CSF amyloid-beta1-42 (HR = 0.999, 95% CI = [0.997, 1.000], p = 0.049). Neither demographic nor clinical variables, nor CSF total tau or p-tau were significantly associated with this endpoint. These results suggest that amyloid deposition in FTD patients may be associated with a higher mortality.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Vieira, D., Durães, J., Baldeiras, I., Santiago, B., Duro, D., Lima, M., et al. (2019). Lower CSF Amyloid-Beta1-42 Predicts a Higher Mortality Rate in Frontotemporal Dementia. Diagnostics (Basel, Switzerland). https://doi.org/10.3390/diagnostics9040162
Vancouver
Vieira D, Durães J, Baldeiras I, Santiago B, Duro D, Lima M, et al. Lower CSF Amyloid-Beta1-42 Predicts a Higher Mortality Rate in Frontotemporal Dementia. Diagnostics (Basel, Switzerland). 2019. doi:10.3390/diagnostics9040162. PMID: 31731494.
BibTeX
@article{vieira2019-31731494,
author = {Vieira, Daniela and Durães, João and Baldeiras, Inês and Santiago, Beatriz and Duro, Diana and Lima, Marisa and Leitão, Maria João and Tábuas-Pereira, Miguel and others},
title = {{Lower CSF Amyloid-Beta1-42 Predicts a Higher Mortality Rate in Frontotemporal Dementia}},
journal = {Diagnostics (Basel, Switzerland)},
year = {2019},
doi = {10.3390/diagnostics9040162},
pmid = {31731494},
url = {https://doi.org/10.3390/diagnostics9040162}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Patients who died during follow up had a significantly lower CSF amyloid-beta1-42 than those who did not.
- The survival analysis demonstrated that an increased death rate was associated with a lower CSF amyloid-beta1-42 (HR = 0.999, 95% CI = [0.997, 1.000], p = 0.049).
- Neither demographic nor clinical variables, nor CSF total tau or p-tau were significantly associated with this endpoint.
- These results suggest that amyloid deposition in FTD patients may be associated with a higher mortality.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Participants99
- Effect sizeHR = 0.999
- Evidence strengthLow
How this study scored 52/100
Published in a peer-reviewed journal. Scored zero for study design and randomised / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record, multi-centre collaboration and free to read, so those were left out: it earned 29 of the 56 points we could judge it on, which is 52 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Diagnostics (Basel, Switzerland)) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2019 — within 10 year(s) of the newest study here |
| Sample size | 1 / 4 | 99 participants |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multi-centre collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 31731494) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 29 / 56 | Scored on 10 of 20 parts. We have no data for the rest, so they are left out: 29 of the 56 points we could judge it on is 52 out of 100. |
| Total | 52 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related studies in Tau biomarkers
Also in Tau biomarkers
56 studies in the library are filed under Tau biomarkers with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Tau biomarkers hub.